Michael Barbella, Managing Editor03.09.24
Continuous glucose monitoring (CGM) technology news intrigued visitors to the MPO website this past week.
Dexcom and Abbott amassed considerable pageviews with updates about their respective CGM devices. Dexcom garnered interest by winning FDA clearance for Stelo, the first glucose biosensor that does not need a prescription, amd Abbott followed suit with new data from two real-world studies that evaluated the use of GLP-1 medicines and its FreeStyle Libre CGM technology in people with Type 2 diabetes. The studies showed people with Type 2 diabetes and an HbA1C ≥8% while using GLP-1 medicines experienced improvements in HbA1C (-1.5%), six months after adding FreeStyle Libre technology to their treatment. Study subjects had a greater HbA1c reduction when using GLP-1 and FreeStyle Libre tech together (-2.4%), compared to using GLP-1 alone (-1.7%).
Besides CGM tech, cybervisitors also favored financial (acquisition), artificial intelligence, and regulatory-related news over the past seven days. Haemonetics took top honors with word of its deal to buy Chicago-based Attune Medical, manufacturer of the ensoETM proactive esophageal cooling device. Attune touts ensoETM as the only FDA-cleared temperature regulation device for esophageal protection during RF cardiac ablation.
Getinge and Royal Philips drove significant traffic, too, though the former gained attention for its regulatory troubles. TÜV SÜD temporarily suspended the CE certificate for the company’s Cardiosave Intra-Aortic Balloon Pump for the second time, effective immediately. The company has six months to correct the device in adherence to corrective guidelines given by TÜV SÜD.
Offsetting Getinge's bureaucratic bumble was Royal Philips' and Synthetic MR's launch of Smart Quant Neuro 3D—an advancement in objective decision support for diagnosis and therapy assessment of brain disorders such as traumatic brain injury and multiple sclerosis.
Dexcom and Abbott amassed considerable pageviews with updates about their respective CGM devices. Dexcom garnered interest by winning FDA clearance for Stelo, the first glucose biosensor that does not need a prescription, amd Abbott followed suit with new data from two real-world studies that evaluated the use of GLP-1 medicines and its FreeStyle Libre CGM technology in people with Type 2 diabetes. The studies showed people with Type 2 diabetes and an HbA1C ≥8% while using GLP-1 medicines experienced improvements in HbA1C (-1.5%), six months after adding FreeStyle Libre technology to their treatment. Study subjects had a greater HbA1c reduction when using GLP-1 and FreeStyle Libre tech together (-2.4%), compared to using GLP-1 alone (-1.7%).
Besides CGM tech, cybervisitors also favored financial (acquisition), artificial intelligence, and regulatory-related news over the past seven days. Haemonetics took top honors with word of its deal to buy Chicago-based Attune Medical, manufacturer of the ensoETM proactive esophageal cooling device. Attune touts ensoETM as the only FDA-cleared temperature regulation device for esophageal protection during RF cardiac ablation.
Getinge and Royal Philips drove significant traffic, too, though the former gained attention for its regulatory troubles. TÜV SÜD temporarily suspended the CE certificate for the company’s Cardiosave Intra-Aortic Balloon Pump for the second time, effective immediately. The company has six months to correct the device in adherence to corrective guidelines given by TÜV SÜD.
Offsetting Getinge's bureaucratic bumble was Royal Philips' and Synthetic MR's launch of Smart Quant Neuro 3D—an advancement in objective decision support for diagnosis and therapy assessment of brain disorders such as traumatic brain injury and multiple sclerosis.